Antigen-specific T cell responses
Start with the study antigen and relevant HLA context. Choose readouts that distinguish a general activation signal from a response to the selected antigen.
| Planning question | Consideration |
|---|---|
| What is the intended recognition event? | Define antigen, HLA context and immune cell source |
| How will specificity be assessed? | Include antigen-negative or irrelevant antigen comparisons where appropriate |
| What will be measured? | Choose activation, expansion or specificity readouts that suit the study |
Target cell cytolysis
Connect the APC configuration to a paired target cell model. The antigen and HLA status of the targets determine which comparisons are interpretable.
Measure cytolysis across defined effector-to-target ratios, with target-only background and suitable antigen/HLA controls. Normalize according to the validated assay method used for the study.
View hTERT & MAGEA3 research examplesAPC gene function studies
Use a custom eDC configuration to investigate the effect of a selected gene modification, including KO. Define the expected biological question, confirmation method and functional endpoint before development.
A matched control and comparable antigen expression, culture state and passage context help interpret an observed change.
Explore custom eDC engineeringPeptide–HLA target nomination
Test whether a candidate peptide–HLA complex is immunogenic and recognized in an HLA-dependent way, before an antibody, CAR-T, ADC or T cell engager is built against it. Targeting the complex rather than a surface protein can add specificity.
| Planning question | Consideration |
|---|---|
| Is the complex immunogenic? | T cell response to the antigen-expressing eDC, with irrelevant antigen and no-peptide controls |
| Is it presented on tumor cells? | Add presentation evidence such as immunopeptidomics, or recognition of targets that express the endogenous antigen |
| How specific is the binder? | Test the binder against related peptide–HLA complexes and against antigen-negative, HLA-mismatched cells |
Screening immunomodulatory biologics
eDCs keep a mature phenotype with costimulatory molecules such as CD40. Agonist and checkpoint antibodies can be compared by their effect on APC activation and T cell priming.
| Planning question | Consideration |
|---|---|
| Is the target present? | Confirm expression, for example CD40 or PD-L1, on the eDC line before screening |
| What is measured? | APC activation markers, cytokines such as IL-12, and priming of antigen-specific T cells |
| Which controls? | A control antibody matched for isotype and Fc format, a stated crosslinking condition and an antibody-free eDC |
| How is the screen qualified? | Agree assay-performance criteria (for example Z′ and CV) and lot-to-lot reproducibility before the screen starts |
APC drug discovery study design
Choose the system around the effect you intend to measure. A change in a T cell readout may reflect altered APC function, effector cell behavior, target cell susceptibility or viability. The study design should distinguish the relevant possibilities.